{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:56:25Z","timestamp":1770350185435,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1124\/jpet.106.116566","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T08:59:24Z","timestamp":1170838764000},"page":"663-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The in Vitro and in Vivo Cardiovascular Effects of \u03949-Tetrahydrocannabinol in Rats Made Hypertensive by Chronic Inhibition of Nitric-Oxide Synthase"],"prefix":"10.1016","volume":"321","author":[{"given":"Saoirse E.","family":"O\u2019Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila M.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.106.116566_bib1","doi-asserted-by":"crossref","unstructured":"Araujo MT, Barker LA, Cabral AM, and Vasquez EC (1998) Inhibition of nitric oxide synthase causes profound enhancement of the Bezold-Jarisch reflex. Am J Hypertens 11: 66\u201372.","DOI":"10.1016\/S0895-7061(97)00302-6"},{"key":"10.1124\/jpet.106.116566_bib2","doi-asserted-by":"crossref","unstructured":"Armstrong JM, Lefevre-Borg F, Scatton B, and Cavero I (1982) Urethane inhibits cardiovascular responses mediated by the stimulation of \u03b1-2 adrenoceptors in the rat. J Pharmacol Exp Ther 223: 524\u2013535.","DOI":"10.1016\/S0022-3565(25)33365-3"},{"key":"10.1124\/jpet.106.116566_bib3","doi-asserted-by":"crossref","unstructured":"Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, et al. (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996\u20132002.","DOI":"10.1161\/01.CIR.0000143230.23252.D2"},{"key":"10.1124\/jpet.106.116566_bib4","doi-asserted-by":"crossref","unstructured":"Ben Amar M (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105: 1\u201325.","DOI":"10.1016\/j.jep.2006.02.001"},{"key":"10.1124\/jpet.106.116566_bib5","doi-asserted-by":"crossref","unstructured":"Benowitz NL and Jones RT (1981) Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21: 214S\u2013223S.","DOI":"10.1002\/j.1552-4604.1981.tb02598.x"},{"key":"10.1124\/jpet.106.116566_bib6","doi-asserted-by":"crossref","unstructured":"Bloom AS, Tershner S, Fuller SA, and Stein EA (1997) Cannabinoid-induced alterations in regional cerebral blood flow in the rat. Pharmacol Biochem Behav 57: 625\u2013631.","DOI":"10.1016\/S0091-3057(96)00475-3"},{"key":"10.1124\/jpet.106.116566_bib7","unstructured":"Crawford WJ and Merritt JC (1979) Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17: 191\u2013196."},{"key":"10.1124\/jpet.106.116566_bib8","doi-asserted-by":"crossref","unstructured":"Dunn WR and Gardiner SM (1995) No evidence for vascular remodelling during hypertension induced by chronic inhibition of nitric oxide synthase in Brattleboro rats. J Hypertens 13: 849\u2013857.","DOI":"10.1097\/00004872-199508000-00005"},{"key":"10.1124\/jpet.106.116566_bib9","doi-asserted-by":"crossref","unstructured":"Ellis EF, Moore SF, and Willoughby KA (1995) Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 269: H1859\u2013H1864.","DOI":"10.1152\/ajpheart.1995.269.6.H1859"},{"key":"10.1124\/jpet.106.116566_bib10","doi-asserted-by":"crossref","unstructured":"Fleming I, Schermer B, Popp R, and Busse R (1999) Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 126: 949\u2013960.","DOI":"10.1038\/sj.bjp.0702381"},{"key":"10.1124\/jpet.106.116566_bib11","doi-asserted-by":"crossref","unstructured":"Gardiner SM, Kemp PA, and Bennett T (1991) Effects of NG-nitro-l-arginine methyl ester on vasodilator responses to adrenaline or BRL 38227 in conscious rats. Br J Pharmacol 104: 731\u2013737.","DOI":"10.1111\/j.1476-5381.1991.tb12496.x"},{"key":"10.1124\/jpet.106.116566_bib12","doi-asserted-by":"crossref","unstructured":"Gardiner SM, March JE, Kemp PA, and Bennett T (2001) Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br J Pharmacol 133: 445\u2013453.","DOI":"10.1038\/sj.bjp.0704100"},{"key":"10.1124\/jpet.106.116566_bib13","doi-asserted-by":"crossref","unstructured":"Gardiner SM, March JE, Kemp PA, and Bennett T (2002a) Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 135: 1889\u20131896.","DOI":"10.1038\/sj.bjp.0704649"},{"key":"10.1124\/jpet.106.116566_bib14","doi-asserted-by":"crossref","unstructured":"Gardiner SM, March JE, Kemp PA, and Bennett T (2002b) Influence of the CB(1) receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 136: 581\u2013587.","DOI":"10.1038\/sj.bjp.0704750"},{"key":"10.1124\/jpet.106.116566_bib15","doi-asserted-by":"crossref","unstructured":"Gatley SJ, Gifford AN, Volkow ND, Lan R, and Makriyannis A (1996) 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307: 331\u2013338.","DOI":"10.1016\/0014-2999(96)00279-8"},{"key":"10.1124\/jpet.106.116566_bib16","doi-asserted-by":"crossref","unstructured":"Henrion D, Dechaux E, Dowell FJ, Maclour J, Samuel JL, Levy BI, and Michel JB (1997) Alteration of flow-induced dilatation in mesenteric resistance arteries of l-NAME treated rats and its partial association with induction of cyclooxygenase-2. Br J Pharmacol 121: 83\u201390.","DOI":"10.1038\/sj.bjp.0701109"},{"key":"10.1124\/jpet.106.116566_bib17","doi-asserted-by":"crossref","unstructured":"Jandhyala BS and Hamed AT (1978) Pulmonary and systemic hemodynamic effects of delta9-tetrahydrocannabinol in conscious and morphine-chloralose-anesthetized dogs: anesthetic influence on drug action. Eur J Pharmacol 53: 63\u201368.","DOI":"10.1016\/0014-2999(78)90268-6"},{"key":"10.1124\/jpet.106.116566_bib18","doi-asserted-by":"crossref","unstructured":"Kawasaki H, Watanabe S, Oishi R, and Ueki S (1980) Effects of delta-9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in rats. Jpn J Pharmacol 30: 493\u2013502.","DOI":"10.1016\/S0021-5198(19)31450-7"},{"key":"10.1124\/jpet.106.116566_bib19","unstructured":"Kosersky DS (1978) Antihypertensive effects of delta9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 233: 76\u201381."},{"key":"10.1124\/jpet.106.116566_bib20","doi-asserted-by":"crossref","unstructured":"Lake KD, Compton DR, Varga K, Martin BR, and Kunos G (1997a) Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281: 1030\u20131037.","DOI":"10.1016\/S0022-3565(24)36714-X"},{"key":"10.1124\/jpet.106.116566_bib21","doi-asserted-by":"crossref","unstructured":"Lake KD, Martin BR, Kunos G, and Varga K (1997b) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29: 1204\u20131212.","DOI":"10.1161\/01.HYP.29.5.1204"},{"key":"10.1124\/jpet.106.116566_bib22","doi-asserted-by":"crossref","unstructured":"Li J, Kaminski NE, and Wang DH (2003) Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 41: 757\u2013762.","DOI":"10.1161\/01.HYP.0000051641.58674.F7"},{"key":"10.1124\/jpet.106.116566_bib23","doi-asserted-by":"crossref","unstructured":"Malinowska B, Kwolek G, and Gothert M (2001) Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 364: 562\u2013569.","DOI":"10.1007\/s00210-001-0498-6"},{"key":"10.1124\/jpet.106.116566_bib24","doi-asserted-by":"crossref","unstructured":"Mendiz\u00e1bal VE, Orliac ML, and Adler-Graschinsky E (2001) Long-term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. Eur J Pharmacol 427: 251\u2013262.","DOI":"10.1016\/S0014-2999(01)01272-9"},{"key":"10.1124\/jpet.106.116566_bib25","doi-asserted-by":"crossref","unstructured":"Navarro-Cid J, Maeso R, Rodrigo E, Munoz-Garcia R, Ruilope LM, Lahera V, and Cachofeiro V (1996) Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs. Am J Hypertens 9: 1077\u20131083.","DOI":"10.1016\/0895-7061(96)00195-1"},{"key":"10.1124\/jpet.106.116566_bib26","doi-asserted-by":"crossref","unstructured":"Niederhoffer N and Szabo B (1999) Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126: 457\u2013466.","DOI":"10.1038\/sj.bjp.0702337"},{"key":"10.1124\/jpet.106.116566_bib27","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan SE, Kendall DA, and Randall MD (2005) The vascular effects of \u03949-tetrahydrocannabinol (THC) and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145: 514\u2013526.","DOI":"10.1038\/sj.bjp.0706218"},{"key":"10.1124\/jpet.106.116566_bib28","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan SE, Kendall DA, and Randall MD (2006) Further characterization of the time-dependent vascular effects of \u03949-tetrahydrocannabinol. J Pharmacol Exp Ther 317: 428\u2013438.","DOI":"10.1124\/jpet.105.095828"},{"key":"10.1124\/jpet.106.116566_bib29","doi-asserted-by":"crossref","unstructured":"Pacher P, Batkai S, and Kunos G (2005) Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 168: 599\u2013625.","DOI":"10.1007\/3-540-26573-2_20"},{"key":"10.1124\/jpet.106.116566_bib30","doi-asserted-by":"crossref","unstructured":"Ritter JM, Ferro A, and Chowienczyk PJ (2006) Relation between beta-adrenoceptor stimulation and nitric oxide synthesis in vascular control. Eur J Clin Pharmacol 62 (Suppl 1): 109\u2013113.","DOI":"10.1007\/s00228-005-0017-7"},{"key":"10.1124\/jpet.106.116566_bib31","doi-asserted-by":"crossref","unstructured":"Ruiz-Marcos FM, Ortiz MC, Fortepiani LA, Nadal FJ, Atucha NM, and Garcia-Estan J (2001) Mechanisms of the increased pressor response to vasopressors in the mesenteric bed of nitric oxide-deficient hypertensive rats. Eur J Pharmacol 412: 273\u2013279.","DOI":"10.1016\/S0014-2999(00)00795-0"},{"key":"10.1124\/jpet.106.116566_bib32","doi-asserted-by":"crossref","unstructured":"Stein EA, Fuller SA, Edgemond WS, and Campbell WB (1996) Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 119: 107\u2013114.","DOI":"10.1111\/j.1476-5381.1996.tb15683.x"},{"key":"10.1124\/jpet.106.116566_bib33","doi-asserted-by":"crossref","unstructured":"Varga K, Lake KD, Huangfu D, Guyenet PG, and Kunos G (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28: 682\u2013686.","DOI":"10.1161\/01.HYP.28.4.682"},{"key":"10.1124\/jpet.106.116566_bib34","doi-asserted-by":"crossref","unstructured":"Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, and Lichtman AH (2005) \u03949-Tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314: 329\u2013337.","DOI":"10.1124\/jpet.104.080739"},{"key":"10.1124\/jpet.106.116566_bib35","unstructured":"Vasquez EC, Cunha RS, and Cabral AM (1994) Baroreceptor reflex function in rats submitted to chronic inhibition of nitric oxide synthesis. Braz J Med Biol Res 27: 767\u2013774."},{"key":"10.1124\/jpet.106.116566_bib36","doi-asserted-by":"crossref","unstructured":"Wagner JA, Jarai Z, Batkai S, and Kunos G (2001) Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423: 203\u2013210.","DOI":"10.1016\/S0014-2999(01)01112-8"},{"key":"10.1124\/jpet.106.116566_bib37","doi-asserted-by":"crossref","unstructured":"Zatz R and Baylis C (1998) Chronic nitric oxide inhibition model six years on. Hypertension 32: 958\u2013964.","DOI":"10.1161\/01.HYP.32.6.958"},{"key":"10.1124\/jpet.106.116566_bib38","doi-asserted-by":"crossref","unstructured":"Zygmunt PM, Andersson DA, and Hogestatt ED (2002) \u03949-Tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22: 4720\u20134727.","DOI":"10.1523\/JNEUROSCI.22-11-04720.2002"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524338406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524338406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.116566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:15:40Z","timestamp":1740003340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524338406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0022356524338406"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.116566","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in Vitro and in Vivo Cardiovascular Effects of \u03949-Tetrahydrocannabinol in Rats Made Hypertensive by Chronic Inhibition of Nitric-Oxide Synthase","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.116566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}